I've heard about a disturbing development: Several pharmaceutical companies may stop their funding of CME because of the current regulatory environment. According to The New York Times, just about every major pharmaceutical company has received federal subpoenas concerning its marketing practices. And, with the new Medicare drug benefit, the government will pay for almost half of all medicine sold in the United States by 2006 — which means scrutiny of pharma firms is only going to intensify ...

Register for Complete Access (Valid Email Required)

By registering on MeetingsNet now, you'll not only unlock the CME at Risk, you'll also gain access to exclusive premium content.

Already registered? here.